@UKHSA This should serve as a wake up call. It's a stark reminder of the ongoing challenges and the urgent need for robust strategies to control TB @UKAPTB@StopTB_ETT
Indeed tackling MDR-TB could help tackle the wider war on superbugs and #AMR. MDR-TB till recently was responsible for a quarter of AMR deaths, though fortunately this will hopefully decrease.
How tackling #TB could help win the war on superbugs. @SahuSuvanand spoke to @FT ahead of UNHLM on #AMR, and said "The battle against TB offers essential lessons for the wider fight against superbugs and should be recognised in its true dimension"
👉 https://t.co/QvQr5lwuiV
How tackling #TB could help win the war on superbugs. @SahuSuvanand spoke to @FT ahead of UNHLM on #AMR, and said "The battle against TB offers essential lessons for the wider fight against superbugs and should be recognised in its true dimension"
👉 https://t.co/QvQr5lwuiV
@UnionConference
Pulmonary TB patients completing treatment are likely to develop pulmonary sequelae including COPD and have significant lung impairment, increased risk of lung infections and cancer. What are we going to do about it? Join us at the UNION room 253.
Application deadline extended to mid November. Great work environment with access to state of the art equipment. Competitive salary with extensive benefits. Plus we get sunsets like this. Please retweet and contact me if any questions.
⭐️Come work with us⭐️Our #Tuberculosis research team is hiring ‼️
2⃣ positions available:
▶️ Medical Research Fellow - in collaboration with @Manhica_CISM
https://t.co/KW2Hm16CPj
▶️ Biostatistician - in collaboration with #TESA network
https://t.co/CuhhKFoRvP
@ISGLOBALorg
The Nov issue of IJTLD includes a multi-country study on the cost of TB services; prevalence of tobacco and cannabis use; work-related ILD; Global Asthma Report; and H-resistant pulmonary TB – see https://t.co/7ADzOBnYOr @TheUnion_TBLH https://t.co/xkV5fZamHx
Great work in this TBnet preprint:
Cost & availability of drugs & treatment regimens & availability of drug resistance testing for tuberculosis in Europe.
G. Günther @gglond, L. Guglielmetti, C. Leu, C. Lange, Frank van Leth @FvLScience, TBnet
https://t.co/ROr7ARynL0
We have reduced our fees for overseas students on the part-time online PGCert in #Tuberculosis. That means our new reduced fees of £3,000 are the same for Home and Overseas students. Apply now to join us in September 22: https://t.co/HC5KupTPPq
Start your postgraduate journey in Tuberculosis with us at QMUL tomorrow 16th June. I will be presenting the course and happy to take any questions.
Quick registration:
https://t.co/NmnxDR0tmL
https://t.co/zyj4UBL7cH @blizard_inst@QMUL@M_Raviglione
Thinking of joining us in September for the part-time, online PGCert in #Tuberculosis? There's still time to register for our programme overview and Q&A webinar taking place next Thursday 16 June at 4pm BST. Register now to meet the #TB team: https://t.co/thkJUCevsI
Join our PGCert #Tuberculosis programme co-directors for an overview and Q&A webinar on Thurs 16 June, 4-5pm BST. Have your questions answered and find out what it's like to study on the course.
Register now👉https://t.co/thkJUCevsI
Accepting applications for Sep 2022 entry now!
Our TB, HIV, Tobacco Control, Bacteriology & Immunology, Nurses & Allied Professionals, and Zoonotic scientific sections all have openings for committee roles. You can work with others and collaborate by joining a committee.
Contact [email protected] for more info
@PaulSaxMD Tebipenem might not be an issue as it’s effective I am more concerned about the use of faropenem sodium in Asia which is known to be inferior to nitrofurantoin in UTI and is probably driving resistance. https://t.co/E1RbaV3E35
The 24th of March is World Tuberculosis (TB) day. We need wider investment globally to:
Support people with TB, provide more effective, affordable and accessible treatment and
ultimately eliminate Tuberculosis worldwide #WorldTBDay#InvestToEndTB#tuberculosis#TB